Lin Yang
Associate Director of Discovery Alloy Therapeutics
Lin Yang is the Associate Director of Discovery at Alloy Therapeutics, where she leads multidisciplinary efforts to identify and advance novel therapeutic candidates. With deep expertise in antibody engineering and directed evolution, Lin oversees early-stage discovery programs from target validation through lead optimization. Her team leverages multiple display platforms to discover highly functional protein binders that align closely with each program’s target product profile. Before joining Alloy, Lin was a postdoctoral fellow in Dr. Sai Reddy’s group at ETH Zürich, where she led research integrating AI/ML with directed evolution to accelerate antibody discovery. Lin earned her PhD in Chemical and Biomolecular Engineering in Dr. Jamie Spangler’s lab at Johns Hopkins University, where her research focused on antibody engineering.
Seminars
T cell receptor–mimic (TCRm) antibodies have emerged as a powerful therapeutic modality, enabling the targeting of intracellular antigens through peptide–MHC complexes that are inaccessible to conventional antibodies. However, their discovery remains highly challenging, constrained by the need for exquisite specificity to distinguish closely related peptide–MHC epitopes, typically modest binding affinities, and the difficulty of preserving native peptide presentation during screening. At Alloy Therapeutics Inc., we address these challenges by integrating high-diversity immune libraries with advanced cell-sorting strategies using target-expressing mammalian cells. This approach enables the discovery of TCRm antibodies that are potent, selective, and developable, seamlessly bridging early binder identification to therapeutic candidate generation through a technology-enabled workflow. Our display platforms support high-resolution mapping of peptide specific landscapes, while AI/ML-guided protein engineering further accelerates the identification and optimization of TCRm candidates with improved affinity, specificity, and favorable developability and safety profiles.
